Incorporated in **1993**, Choksi Laboratories Limited (**CLL**) is a premier Indian provider of contract testing and analytical services. Operating as a **Small to Medium Enterprise (MSME)**, the company serves as a critical third-party quality assurance partner for diverse industrial sectors. CLL provides research support, regulatory compliance testing, and technical consultancy, positioning itself as a vital link in the supply chains of the pharmaceutical, food, and environmental industries. --- ### **Diversified Service Portfolio & Market Segments** CLL operates under a single reportable segment—**Analysis and Testing**—but maintains a highly diversified service offering that mitigates sector-specific downturns: * **Pharmaceutical & Biotech Testing:** Comprehensive analytical and stability testing services to ensure drug safety and efficacy. * **Food & Agricultural Products:** Testing for food safety, residue analysis, and microbiome profiles, driven by stringent **FSSAI** and **AGMARK** regulations. * **Environmental Services:** Monitoring and analysis of air, water, and soil, governed by **MOEF** and **State Pollution Control Board** norms. * **Calibration Services:** High-precision instrument calibration for organizations maintaining **ISO** certifications. * **Construction Material Testing:** Quality analysis for materials used in large-scale real estate and infrastructure projects. --- ### **Strategic Infrastructure & Geographic Footprint** The company operates a **Central Laboratory** in Indore, supported by a strategic network of branch laboratories located in India’s primary industrial hubs. | Facility Type | Location | Strategic Focus | | :--- | :--- | :--- | | **Registered Office & Central Lab** | **Indore, Madhya Pradesh** | Core testing operations, administration, and R&D. | | **Branch Laboratory** | **Vapi, Gujarat** | Chemical and industrial hub support. | | **Branch Laboratory** | **Vadodara, Gujarat** | Engineering and pharmaceutical support. | | **Branch Laboratory** | **Verna, Goa** | Pharmaceutical and biotech corridor. | | **Branch Laboratory** | **Panchkula, Haryana** | Northern India industrial and food testing. | | **New Laboratory (Upcoming)** | **Patna, Bihar** | Dedicated facility for the **NPDD** Quality Milk Program. | --- ### **Regulatory Moats & Accreditations** CLL’s competitive advantage is anchored in its extensive list of national and international certifications, which act as a significant barrier to entry: * **NABL Accreditation:** Based on **ISO/IEC 17025** guidelines, providing international recognition through **ILAC**. * **Regulatory Approvals:** Recognized by the **U.S. FDA**, **Indian FDA**, **BIS**, **MOEF**, **FSSAI**, and **APEDA**. * **Pioneering Status:** The first laboratory in Central India to launch **Vendor Assessment** programs for the edible oil industry and dedicated instrument calibration services. --- ### **Growth Strategy & Future Initiatives** The company is currently executing a capacity expansion across its **five units** to capture double-digit growth in the analytical testing market. * **Government Partnerships:** CLL has entered a landmark agreement with the **Bihar State Milk Co-operative Federation Limited (COMFED)**. This project is a key component of the Central Government’s **Quality Milk Program** under the **National Programme for Dairy Development (NPDD)**. * **Sector Expansion:** Increasing focus on niche areas such as **trace metals**, **residue analysis**, and **water/soil analysis**. * **Macro Drivers:** Leveraging the **'Make in India'** and **'Atmanirbhar Bharat'** initiatives, which mandate stricter domestic quality and environmental standards. * **Leadership Continuity:** To ensure stable execution, the company re-appointed Mr. Vyangesh Choksi as **Whole-time Director** for a **5-year term** (through **August 2030**) and appointed Mr. Ritik Pavecha as an **Independent Director** (starting **February 2026**). --- ### **Financial Performance & Capital Discipline** CLL has demonstrated a trajectory of rising revenue and aggressive deleveraging. For **FY 2024-25**, revenue grew by **13.5%** due to improved productivity. **Comparative Financial Summary:** | Particulars (₹ in Lacs) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Revenue from Operations** | **4,184.94** | **3,685.92** | | **Net Profit After Tax (PAT)** | **152.33** | **110.98** | | **Net Debt** | **2,854.41** | **3,021.57** | | **Gearing Ratio** | **1.21** | **1.36** | **Debt Management:** The company has successfully reduced its **Gearing Ratio** from **2.06** in 2022 to **1.21** in 2025. It recently transitioned its **Cash Credit** facility to the **State Bank of India (SBI)** with a sanctioned limit of **₹ 5.9 Crore**. To optimize interest costs, CLL utilizes **Foreign Currency Loans** hedged with **forward covers**. --- ### **Risk Profile & Mitigation Framework** Management employs a robust internal control system reviewed by the **Audit Committee** to manage operational and financial risks. #### **1. Cybersecurity & IT Resilience** In **May 2025**, CLL faced a **ransomware attack** that temporarily compromised its servers. * **Response:** Data was fully restored by **May 31, 2025**, via off-site backups. * **Mitigation:** The company has since implemented **multi-layered security**, firewalls, and endpoint protection. It is now fully compliant with **Rule 3(1) of the Companies (Accounts) Rules, 2014**, maintaining an **audit trail (edit log)** for all financial records. #### **2. Financial Sensitivity** | Risk Factor | Impact Analysis | Mitigation | | :--- | :--- | :--- | | **Interest Rate** | A **1% increase** impacts annual profit by **~₹ 28.07 Lacs**. | Monitoring of floating rates; evaluation of swaps. | | **Foreign Exchange** | Volatility in **INR/USD** affects equipment imports. | Use of **forward covers** and SBI foreign currency loans. | | **Credit Risk** | Potential defaults on receivables. | Use of **Expected Credit Loss (ECL)** models. | #### **3. Operational Challenges** * **Human Capital:** High dependency on **skilled manpower**; requires continuous training to meet evolving regulatory standards. * **Market Competition:** Pricing pressure from unorganized local players. * **Capital Intensity:** Ongoing need for high capital expenditure to upgrade to high-end testing technology.